Longevity.Technology UNLOCKED

Longevity.Technology
  • 5.0 (4)
  • Health & Fitness
  • Updated Weekly

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem. 🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space. If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.

  1. 1d ago

    Why Women May Need a Completely Different Longevity Playbook | Longevity News Roundup—Week 32, 2026

    Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman explores whether aging research has overlooked half the population, why supplement quality is becoming a scientific issue, how NAD+ science is moving into pharmaceutical development, and what superagers reveal about the limits of genetic prediction. A new $7.5 million NIH-funded center at USC will investigate sex differences in aging after decades of male-biased research. The initiative could reshape biomarkers, clinical trials, and personalized longevity interventions.Swiss longevity company Timeline won a $5.3 million judgment against sellers falsely marketing products as containing urolithin A. The ruling reinforces that scientific evidence depends on products containing the same ingredient and dose used in clinical research.Niagen Bioscience has partnered with Evotec to advance NB4168, an oral NAD+ small molecule for a rare pediatric neurodegenerative disease. The collaboration highlights how longevity companies are increasingly translating supplement science into regulated drug development.Researchers found that superagers shared similar Alzheimer's genetic risk profiles with cognitively average older adults. Rather than supporting a DNA destiny narrative, the findings point toward resilience mechanisms that future studies will explore through biomarkers, immune profiling, brain imaging, and lifestyle. ---------- News & References: What if aging research has been studying the wrong sex? → https://longevity.technology/news/what-if-aging-research-has-been-studying-the-wrong-sex/Timeline wins $5.3m in fake urolithin A case → https://longevity.technology/news/timeline-wins-5-3m-in-fake-urolithin-a-case/Niagen Bioscience teams up with Evotec to prepare rare disease drug for human trials → https://longevity.technology/news/niagen-bioscience-teams-up-with-evotec-to-prepare-rare-disease-drug-for-human-trials/SuperAgers challenge the DNA destiny narrative → https://longevity.technology/news/superagers-challenge-the-dna-destiny-narrative/ ---------- Hosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠

  2. 5d ago

    Why “Normal” Blood Results Could Be Misleading

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: www.getstride.com/unlocked/ ---------- Guest: Andrew Steele Co-Founder & CEO of Stride LinkedIn: www.linkedin.com/in/andrewsteeleathlete/ Website: www.getstride.com/eu/ ---------- What if the future of healthcare isn't about finding disease earlier, but preventing it from developing in the first place? Phil Newman and Dr. Nina Patrick sit down with Andrew Steele, founder and CEO of Stride and former Olympic sprinter, to explore how personalized health is evolving beyond wearables, blood tests, and genetic reports into a truly integrated model of prevention. Drawing on his experience as an elite athlete and entrepreneur, Andrew explains why collecting more health data isn't enough, and why the real challenge is helping people make better decisions that actually change long term behavior. The conversation explores how Stride combines genetics, microbiome testing, advanced blood biomarkers, wearable data, and practitioner coaching into a single preventive health platform designed to prioritize the actions that matter most. Rather than overwhelming people with hundreds of recommendations, Andrew argues that sustainable health improvement comes from identifying a few highly personalized interventions that create momentum for broader lifestyle change. They also discuss how longitudinal testing can reveal patterns that traditional healthcare often misses. Instead of relying on whether a biomarker sits inside or outside a population reference range, Andrew explains why understanding an individual's direction of travel over time may provide much earlier signals of future health risks. The discussion explores how integrating multiple biological data layers could eventually allow AI powered systems to identify preclinical risk years before disease develops. The episode also examines the growing role of consumer health technologies, the limitations of existing healthcare systems, and why prevention increasingly sits outside traditional medicine. Andrew shares why he believes younger generations are embracing longevity as part of their identity, how behavioral psychology influences successful health interventions, and why human coaching remains essential even in an AI driven future. In this episode, you’ll learn: Why personalized health requires more than DNA tests or wearable devicesHow combining genetics, microbiome data, blood biomarkers, and lifestyle creates a more complete picture of health Why focusing on three meaningful actions is more effective than dozens of recommendations How longitudinal biomarker tracking may detect risk before conventional clinical thresholds are reached Why AI works best when combined with experienced healthcare practitioners If you want to understand where personalized medicine is heading, how AI could transform prevention, and why the next generation of healthcare may be built around continuous, individualized guidance rather than reactive treatment, this episode offers an insightful look at the future of longevity. Subscribe for weekly conversations exploring longevity science, precision medicine, biotechnology, AI, and the innovations shaping healthier, longer lives.

  3. Jul 31

    One-Shot Gene Therapies & Peptides | Longevity News Roundup—Week 31, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine new Alzheimer's therapies, the growing debate around experimental peptides, expanding access to investigational treatments, rapid advances in metabolic disease and encouraging progress in longevity gene therapy. Voyager Therapeutics reported that its investigational gene therapy VY1706 reduced tau protein by up to 75% in non-human primates for six months after a single intravenous dose, using a novel blood-brain barrier delivery approach.An advisory panel to the US Food and Drug Administration recommended broader access to compounded wellness peptides despite concerns over limited human evidence, highlighting the growing tension between consumer demand, regulatory oversight and the need for robust clinical trials.Vandria announced that its oral mitochondrial therapy VNA-318  safely reached the brain in its first human study, supporting once-daily dosing ahead of planned Alzheimer's trials.Montana advanced Right to Try legislation that could expand patient access to investigational therapies beyond traditional approval pathways, raising new questions about evidence, transparency and responsible implementation.D&D Pharmatech reported that its once-weekly dual GLP-1/glucagon receptor agonist zabopegdutide rapidly reduced liver fat and stiffness, with benefits seen even among participants who experienced minimal weight loss.Genflow Biosciences reported positive early results from its SIRT6 gene therapy trial in aging dogs, supporting the growing use of companion animals as a bridge toward future human longevity therapies ---------- News & References: Voyager’s single-dose gene therapy cuts tau by 75% → https://longevity.technology/news/voyagers-single-dose-gene-therapy-cuts-tau-by-75/FDA panel backs peptides over its own scientists → https://longevity.technology/news/fda-panel-backs-peptides-over-its-own-scientists/Vandria’s experimental Alzheimer’s pill proves safe, reaches target in first human study → https://longevity.technology/news/vandrias-experimental-alzheimers-pill-proves-safe-reaches-target-in-first-human-study/Montana takes next step on experimental therapies → https://longevity.technology/news/montana-takes-next-step-on-experimental-therapies/Zabopegdutide shows rapid, weight-independent liver benefits in Phase 2 → https://longevity.technology/news/zabopegdutide-shows-rapid-weight-independent-liver-benefits-in-phase-2/Genflow reports positive early results in aging-dog gene therapy trial → https://longevity.technology/news/genflow-reports-positive-early-results-in-aging-dog-gene-therapy-trial/

  4. Jul 27

    Can Longevity Become Public Policy?

    Hosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠ Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠ ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: ⁠rechargehealthas.sjv.io/jRQyQ5⁠ ---------- Guests: Dylan V. Livingston Founder and CEO of The Alliance for Longevity Initiatives (A4LI) LinkedIn: ⁠www.linkedin.com/in/dylan-v-livingston/⁠ Website: ⁠a4li.org/⁠ ---------- What if the biggest barrier to longer, healthier lives isn't scientific discovery, but public policy? In this episode, Phil Newman and Dr. Nina Patrick sit down with Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), to explore how Washington is becoming one of the most important frontiers in healthy aging. Based on his unusual journey from political campaigning to longevity advocacy, Dylan explains why extending healthy lifespan requires more than innovative biotechnology. It also requires regulatory reform, stronger public investment, and policymakers who understand the biology of aging. From his work advancing state-level Right to Try legislation to proposals for new FDA pathways that recognize therapies targeting multiple age-related diseases, he shares how policy could dramatically accelerate the translation of longevity science into clinical practice. The conversation explores the growing role of biomarkers, surrogate endpoints, and ARPA-H's PROSPR program in creating clearer regulatory pathways for aging interventions. Dylan also discusses proposals for expanding NIH support for aging biology research, why the current funding landscape remains misaligned with the burden of age-related disease, and how advocacy organizations can help bridge the gap between researchers, biotech companies, regulators, and elected officials. They also examine whether the United States can maintain its leadership in longevity innovation as countries around the world invest in their own longevity ecosystems, and why creating the right incentives today could determine who leads the next generation of medicine. In this episode, you’ll learn: Why public policy may become the biggest accelerator, or bottleneck, for longevity science.How a proposed multi-disease therapeutic designation could speed the development of aging interventions.- Why validated biomarkers and surrogate endpoints are essential for future FDA approval pathways.How Right to Try legislation could expand safe access to experimental longevity therapies while generating valuable clinical data.Why stronger NIH investment, regulatory reform, and grassroots advocacy are all needed to bring longevity medicine into mainstream healthcare. If you want to understand how longevity is evolving from a scientific discipline into a healthcare and public policy movement, this episode explores the people, institutions, and regulatory decisions that could shape the future of healthy aging for decades to come. Subscribe for weekly conversations exploring longevity science, biotechnology, preventative medicine, and the innovations transforming how we live longer and better.

  5. Jul 24

    The First Real Longevity Drugs Are Getting Closer | Longevity News Roundup – Week 30, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: https://rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health. Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study.Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration.Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry.Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures.Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing. ---------- News & References: Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/

  6. Jul 20

    Are You Taking Too Many Supplements? Gut Health, Blood Tests & Personalized Longevity

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- Guests: Aaron Deere Health and Performance Director of HOOKE London LinkedIn: www.linkedin.com/in/aaron-deere-129079128/ Website: www.hooke.london/ Dr Jean-Marc Sobczyk Integrative Medicine & Longevity Physician of HOOKE London LinkedIn: www.linkedin.com/in/jean-marc-sobczyk/ Website: www.hooke.london/ ---------- What if the future of longevity isn't about taking more supplements, but taking fewer, better ones? In this episode, Phil Newman and Dr. Nina Patrick are joined by HOOKE London experts Aaron Deere, Health and Performance Director, and Dr. Jean-Marc Sobczyk, an integrative longevity physician, to explore how personalized nutrition, biomarker testing, and gut health are reshaping the future of preventive healthcare. Drawing on years of clinical experience, they challenge the growing culture of "stacking" supplements without evidence, explaining why many people unknowingly oversupplement certain nutrients while remaining deficient in others. Through real-world case studies, they discuss why comprehensive blood testing should come before supplementation, how personalized formulations outperform generic multivitamins, and why regular monitoring is essential as your health, lifestyle, and physiology evolve over time. The conversation also explores one of the most exciting frontiers in longevity: the microbiome. Aaron and Dr. Sobczyk explain why gut health is far more complex than simply taking probiotics, why the same stool sample can produce completely different results when analyzed by different laboratories, and how emerging AI-powered research could unlock more targeted microbiome therapies for inflammation, cognitive health, mood, skin aging, and disease prevention. Throughout the conversation, one message remains clear: longevity isn't about chasing every new technology or buying every trending supplement. It's about understanding your unique biology and making informed decisions based on data, evidence, and continuous monitoring rather than marketing claims or social media advice. In this episode, you’ll learn: Why taking more supplements can increase the risk of nutrient overload and unnecessary expense.How blood biomarkers can uncover hidden deficiencies like iron, vitamin D, and omega-3 insufficiency while identifying oversupplementation. Why microbiome testing remains useful despite inconsistent laboratory results, and how to interpret those findings in clinical practice. How GLP-1 therapies can support healthspan when combined with strength training, adequate protein intake, and lifestyle change. Why sleep, nutrition, cardiovascular fitness, muscle health, and consistent monitoring still outperform the latest longevity trends. Whether you're building your first supplement protocol or refining an advanced longevity strategy, this conversation offers a practical framework for moving beyond guesswork and toward truly personalised health optimisation. It connects emerging science with real-world clinical experience, showing why testing, monitoring, and individualisation are becoming the new foundation of preventive medicine. Subscribe for weekly episodes exploring longevity science, precision medicine, preventative healthcare, and the innovations shaping how we live longer, healthier lives.

  7. Jul 17

    Is Longevity Becoming the Next Global Race? | Longevity News Roundup — Week 29, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine BioAge's inflammation therapy, Alzheimer's advances, China's growing biotech influence, protein repair research, menopause science and US longevity policy. BioAge dosed the first patient in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inflammasome inhibitor discovered through human longevity datasets rather than traditional disease-first drug discovery.Alzheon presented new analyses showing reduced brain swelling, preserved brain structure and encouraging biomarker and cognitive signals for valiltramiprosate, despite the original Phase 3 trial missing its primary endpoint. Confirmation studies are still needed.Kailera licensed its entire GLP-1 pipeline from China's Jiangsu Hengrui, highlighting growing US concerns over China's expanding role in drug innovation and obesity therapeutics.Revel Pharmaceuticals enzymatically removed advanced glycation end product (CML) damage from aged human tissues ex vivo, challenging long-held assumptions that some forms of molecular aging are irreversible.Elysium reported early pilot data suggesting its NAD+ supplement Basis reduced several menopause symptoms within seven days while also shifting estrogen metabolism biomarkers. Larger randomized trials are now needed.US policymakers and regulators outlined new frameworks supporting geotherapeutics, aging biomarkers and reimbursement, signalling growing federal momentum behind healthspan-focused medicine. ---------- News & References: BioAge doses first patient in Phase 2 trial of new cardiovascular drug → https://longevity.technology/news/bioage-doses-first-patient-in-phase-2-trial-of-new-cardiovascular-drug/Fresh analyses reshape Alzheon’s oral Alzheimer’s drug → https://longevity.technology/news/fresh-analyses-reshape-alzheons-oral-alzheimers-drug/Kailera’s oral obesity pill posts Phase 3 gains → https://longevity.technology/news/kaileras-oral-obesity-pill-posts-phase-3-gains/When irreversible no longer means forever → https://longevity.technology/news/when-irreversible-no-longer-means-forever/Elysium pilot study links Basis to reduced menopause symptoms → https://longevity.technology/news/elysium-pilot-study-links-basis-to-reduced-menopause-symptoms/US longevity policy takes center stage in Washington → https://longevity.technology/news/us-longevity-policy-takes-center-stage-in-washington/

  8. Jul 13

    The Genetic Clues That Could Predict How You Age

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- Guests: Professor Ronjon Nag, OBE President of the R42 Group, CEO and Founder of Agemica and Board Advisor at Genomelink and YourRoots LinkedIn: www.linkedin.com/in/ronjonnag/ Website: www.r42group.com/, agemica.com, app.superbio.ai, genomelink.io, yourroots.com ---------- What if your DNA and AI could become one of the most powerful tools for preventing disease, optimizing health, and extending healthy lifespan? Phil Newman and Dr. Nina Patrick sit down with Ronjon Nag, OBE, President of R42, CEO of Aegemica and Superbio.ai, and Adjunct Professor in Genetics at the Stanford School of Medicine, to explore how artificial intelligence is reshaping genomics and why we're entering a new era of personalized healthcare. Ronjon explains why most diseases are far more complex than single-gene mutations, and why understanding biology increasingly requires combining genetics with biomarkers, clinical records, lifestyle, and AI. He shares why genetics should be viewed as a lifelong health blueprint rather than a one-time report, and how future AI systems may allow people to interact with their own biology in entirely new ways. The conversation also explores why medicine is shifting toward prediction rather than reaction, how AI is helping researchers identify disease patterns hidden inside massive biological datasets, and why better data could dramatically accelerate drug discovery and preventative healthcare. Ronjon also discusses one of his boldest projects yet: developing peptide-based vaccines that target multiple aging pathways simultaneously. By combining AI with large-scale biological datasets, his team hopes to train the immune system to recognize and eliminate damaged cells before they contribute to age-related disease. In this episode, you’ll learn: Why most diseases are influenced by thousands of genes, not just oneHow AI is making genetics more useful for everyday healthcare Why combining genetics with biomarkers creates better health insights How preventative medicine is moving toward personalized risk prediction The science behind peptide vaccines targeting aging pathways Why AI may soon let you "talk" to your own biology If you're interested in AI, biotechnology, longevity science, and the future of healthcare, this episode offers an inside look at the technologies that could fundamentally change how we prevent disease and extend healthy lifespan. Subscribe for weekly conversations exploring longevity science, biotechnology, and the innovations helping people live healthier, longer lives.

See All (63)

Trailer

Ratings & Reviews

5
out of 5
4 Ratings

About

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem. 🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space. If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.

Information

You Might Also Like